CrystalGenomics Inc Cash Flow Conversion Efficiency
CrystalGenomics Inc cash flow conversion efficiency. Based on the latest financial reports, CrystalGenomics Inc (083790) has a cash flow conversion efficiency ratio of -0.129x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-11.39 Billion ≈ $-7.72 Million USD) by net assets (₩87.96 Billion ≈ $59.61 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of CrystalGenomics Inc (2014–2024)
Cash flow conversion efficiency of CrystalGenomics Inc from 2014 to 2024. This chart illustrates how CrystalGenomics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 083790 share price today for real-time trading data and today's change.
CrystalGenomics Inc Cash Flow Conversion Ratio Explained
CrystalGenomics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
CrystalGenomics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CrystalGenomics Inc ranked by their cash flow conversion efficiency. Also see CrystalGenomics Inc (083790) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cadence Opportunities Fund Ltd
AU:CDO
|
0.000x |
|
BCB Bhd
KLSE:6602
|
0.188x |
|
Goldenstone Acquisition Ltd
NASDAQ:GDST
|
0.004x |
|
Perusahaan Sadur Timah Malaysia Perstima Bhd
KLSE:5436
|
0.038x |
|
Coda Minerals Ltd
AU:COD
|
-0.136x |
|
Chonburi Concrete Product Public Company Limited
BK:CCP
|
0.074x |
|
Chinyang Poly
KO:010640
|
0.004x |
|
Aspermont Ltd
AU:ASP
|
0.082x |
Annual Cash Flow Conversion Efficiency for CrystalGenomics Inc (2014–2024)
The table below shows the annual cash flow conversion efficiency of CrystalGenomics Inc from 2014 to 2024. Review how much free cash does CrystalGenomics Inc generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩98.52 Billion ≈ $66.76 Million |
₩-25.85 Billion ≈ $-17.52 Million |
-0.262x | -17.63% |
| 2023-12-31 | ₩145.29 Billion ≈ $98.46 Million |
₩-32.41 Billion ≈ $-21.96 Million |
-0.223x | -72.08% |
| 2022-12-31 | ₩188.28 Billion ≈ $127.59 Million |
₩-24.40 Billion ≈ $-16.54 Million |
-0.130x | -135.12% |
| 2021-12-31 | ₩207.84 Billion ≈ $140.85 Million |
₩-11.46 Billion ≈ $-7.77 Million |
-0.055x | +27.74% |
| 2020-12-31 | ₩214.76 Billion ≈ $145.54 Million |
₩-16.38 Billion ≈ $-11.10 Million |
-0.076x | -59.32% |
| 2019-12-31 | ₩149.05 Billion ≈ $101.01 Million |
₩-7.14 Billion ≈ $-4.84 Million |
-0.048x | -632.04% |
| 2018-12-31 | ₩184.47 Billion ≈ $125.01 Million |
₩-1.21 Billion ≈ $-817.78K |
-0.007x | -136.69% |
| 2017-12-31 | ₩91.59 Billion ≈ $62.07 Million |
₩1.63 Billion ≈ $1.11 Million |
0.018x | +117.86% |
| 2016-12-31 | ₩83.16 Billion ≈ $56.36 Million |
₩-8.30 Billion ≈ $-5.63 Million |
-0.100x | -51.96% |
| 2015-12-31 | ₩71.94 Billion ≈ $48.75 Million |
₩-4.73 Billion ≈ $-3.20 Million |
-0.066x | +3.72% |
| 2014-12-31 | ₩55.03 Billion ≈ $37.29 Million |
₩-3.75 Billion ≈ $-2.54 Million |
-0.068x | -- |
About CrystalGenomics Inc
CrystalGenomics, Inc., a biopharmaceutical company, discovers and develops structural chemoproteiomics-based drugs in Korea. Its lead development candidate is NSAID (CG100649), which is a tissue specific anti-inflammatory agent with cardiovascular, gastrointestinal, and renal safety profiles that has completed Phase IIa clinical trial. The company's drug candidates also include CG200745, a histon… Read more